S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NASDAQ:ICPT

Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

$13.59
-0.60 (-4.23%)
(As of 03/22/2023 05:24 PM ET)
Add
Compare
Today's Range
$13.57
▼
$14.41
50-Day Range
$14.19
▼
$21.71
52-Week Range
$10.81
▼
$21.86
Volume
618,567 shs
Average Volume
792,221 shs
Market Capitalization
$566.30 million
P/E Ratio
2.10
Dividend Yield
N/A
Price Target
$25.70

Intercept Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
89.1% Upside
$25.70 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.13
Upright™ Environmental Score
News Sentiment
0.86mentions of Intercept Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.60) to $0.25 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

93rd out of 983 stocks

Pharmaceutical Preparations Industry

30th out of 478 stocks

See Top Rated MarketRank™ Stocks Here

ICPT stock logo

About Intercept Pharmaceuticals (NASDAQ:ICPT) Stock

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Stock News Headlines

March 17, 2023 | americanbankingnews.com
Q1 2023 EPS Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Raised by B. Riley
March 13, 2023 | finance.yahoo.com
Intercept (ICPT) Stock Down on FDA Committee Update on NDA
March 22, 2023 | Investing Daily (Ad)
Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
March 13, 2023 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intercept Pharma (ICPT) and Takeda Pharmaceutical Company (TAK)
March 12, 2023 | americanbankingnews.com
Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Down 7.3%
March 11, 2023 | finance.yahoo.com
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) down to US$672m market cap, but institutional owners may not be as affected after a year of 8.0% returns
March 10, 2023 | finance.yahoo.com
Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH
March 10, 2023 | marketwatch.com
Intercept Says FDA Sets AdCom Meeting on Obeticholic Acid >ICPT
March 22, 2023 | Investing Daily (Ad)
Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
March 10, 2023 | markets.businessinsider.com
JMP Securities Keeps Their Hold Rating on Intercept Pharma (ICPT)
March 10, 2023 | msn.com
Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months
March 9, 2023 | finance.yahoo.com
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023
March 3, 2023 | finance.yahoo.com
Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase
March 3, 2023 | finance.yahoo.com
Q4 2022 Intercept Pharmaceuticals Inc Earnings Call
March 2, 2023 | markets.businessinsider.com
B.Riley Financial Keeps Their Buy Rating on Intercept Pharma (ICPT)
March 2, 2023 | finance.yahoo.com
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance
March 1, 2023 | msn.com
Preview: Intercept Pharmaceuticals's Earnings
February 23, 2023 | finance.yahoo.com
Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
February 13, 2023 | finance.yahoo.com
Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval
January 24, 2023 | seekingalpha.com
Intercept: Huge Potential Upsides With Binary Catalyst Unlocking
January 20, 2023 | finance.yahoo.com
Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?
January 19, 2023 | finance.yahoo.com
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
January 13, 2023 | finance.yahoo.com
Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why
January 5, 2023 | finance.yahoo.com
Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
January 4, 2023 | finance.yahoo.com
Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
December 23, 2022 | marketwatch.com
Intercept Pharmaceuticals Resubmits New Drug Application for Obeticholic Acid
December 23, 2022 | finance.yahoo.com
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
See More Headlines
Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Company Calendar

Last Earnings
11/03/2021
Today
3/22/2023
Next Earnings (Estimated)
5/05/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ICPT
CUSIP
45845P10
CIK
1270073
Web
www.interceptpharma.com
Phone
(646) 747-1000
Fax
646-747-1001
Employees
437
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.70
High Stock Price Forecast
$49.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+81.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$6.47
Trailing P/E Ratio
2.19
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$221.82 million
Net Margins
70.39%
Pretax Margin
-61.20%
Return on Equity
N/A
Return on Assets
-30.11%

Debt

Debt-to-Equity Ratio
2.40
Current Ratio
2.35
Quick Ratio
2.35

Sales & Book Value

Annual Sales
$285.71 million
Price / Sales
2.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.25 per share
Price / Book
6.31

Miscellaneous

Outstanding Shares
41,670,000
Free Float
32,919,000
Market Cap
$591.30 million
Optionable
Optionable
Beta
1.29

Key Executives

  • Jerome B. Durso
    President, Chief Executive Officer & Director
  • Bryan Ball
    Chief Quality Officer & Senior VP-Operations
  • Andrew Saik
    Chief Financial Officer
  • M. Michelle Berrey
    Chief Medical Officer
  • Linda M. Richardson
    Chief Commercial Officer & Executive VP

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ICPT Stock - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICPT shares.
View ICPT analyst ratings or view top-rated stocks.

What is Intercept Pharmaceuticals' stock price forecast for 2023?

7 equities research analysts have issued 1-year target prices for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $14.00 to $49.00. On average, they expect the company's share price to reach $25.70 in the next year. This suggests a possible upside of 81.1% from the stock's current price.
View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts.

How have ICPT shares performed in 2023?

Intercept Pharmaceuticals' stock was trading at $12.37 at the start of the year. Since then, ICPT stock has increased by 14.7% and is now trading at $14.19.
View the best growth stocks for 2023 here.

When is Intercept Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our ICPT earnings forecast.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.89. The biopharmaceutical company had revenue of $92.80 million for the quarter, compared to the consensus estimate of $83.04 million. The firm's revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.01) EPS.

What ETFs hold Intercept Pharmaceuticals' stock?

ETFs with the largest weight of Intercept Pharmaceuticals (NASDAQ:ICPT) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $310.00 million-$340.00 million, compared to the consensus revenue estimate of $321.92 million.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.36%), Renaissance Technologies LLC (1.71%), Macquarie Group Ltd. (1.62%), Geode Capital Management LLC (1.41%), ExodusPoint Capital Management LP (1.28%) and Jupiter Asset Management Ltd. (1.02%). Insiders that own company stock include Christian Weyer, David A Ford, Jason Campagna, Paolo Fundaro, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $14.19.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $591.30 million and generates $285.71 million in revenue each year. The biopharmaceutical company earns $221.82 million in net income (profit) each year or $6.47 on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

The company employs 437 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.

This page (NASDAQ:ICPT) was last updated on 3/22/2023 by MarketBeat.com Staff